Loading...
Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Table of Content

    Volume 30 Issue 1
    26 January 2025
    Mechanism of doxorubicin/copper complex induced cuproptosis in hepatocellular carcinoma cells
    LIU Jing, LEI Guojie, CAO Jinghao, YU Lingyan, DU Jing, WANG Ying
    2025, 30(1):  1-10.  doi:10.12092/j.issn.1009-2501.2025.01.001
    Asbtract ( 72 )   PDF (5391KB) ( 24 )  
    Related Articles | Metrics
    AIM: To explore the mechanism of doxorubicin/copper (DOX/Cu) complex induced copper death in hepatocellular carcinoma cells. METHODS: Human hepatocellular carcinoma cell line Huh7 was treated with DOX/Cu 0, 2.5, 4, 7.5, 10 and 12.5 μmol/L. The cell viability was detected by CCK-8 method. The cell proliferation level was observed by laser microscopy and proliferation kit. The cell invasion ability was determined by cell scratch assay. The flow cytometry was used to detect intracellular reactive oxygen species (ROS) and copper ion levels. And the western blot was used to detect intracellular iron-sulfur cluster proteins expression levels. RESULTS: With the increase of DOX/Cu concentration, cell viability, cell proliferation and invasion ability decreased gradually. The copper ion chelating agent (TTM) can significantly restore the effects of DOX/Cu on cell viability. After DOX/Cu treatment, intracellular copper ion and ROS levels related to coproptosis were significantly increased, accompanied by the loss of iron-sulfur cluster proteins. CONCLUSION: DOX/Cu can inhibit hepatocellular carcinoma cells through cuproptosis.
    Nrf1 attenuates neuronal injury caused by oxygen glucose deprivation/reperfusion via inhibiting apoptosis
    XIA Rongsong, YANG Jing, WANG Hong, PENG Zhe, ZHAO Yibei, YANG Junqing
    2025, 30(1):  11-19.  doi:10.12092/j.issn.1009-2501.2025.01.002
    Asbtract ( 29 )   PDF (3364KB) ( 33 )  
    Related Articles | Metrics
    AIM: To investigate the effects of Nrf1 on neuronal apoptosis treated by oxygen-glucose deprivation/reperfusion and the mechanism. METHODS: Single-cell sequencing data was analyzed by GEO database, and the correlation of Nrf1 expression with apoptotic pathways evaluated based on GSVA package calculations. PC12 cells and primary neurons were divided into the Normal group, the OGD/R group, the OGD/R+ siRNA-NC group, and the OGD/R+ Nrf1-siRNA-2 group. Cell images was observed by laser scanning confocal microscopy; the viability of cells were detected by MTT assay; the apoptosis of cells were detected by flow cytometry; DHE fluorescent probe to detect ROS levels, the protein expression of Nrf1,bcl-2 and Bax were detected by Western blot; and nuclear translocation was observed by laser scanning confocal microscope. RESULTS: The results of biosignature analysis revealed that Nrf1 was mainly enriched in the apoptotic pathway; compared with normal group, the cell body became smaller, synapse broke, cells clustered in PC12 cells and primary neurons with OGD/R treated, and the vitality of PC12 cells and neuronal were decreased significantly (P<0.01); ROS levels were significantly higher (P<0.01), the expressions of Nrf1 and Bax were increased significantly, and the expression of bcl-2 was decreased significantly (P<0.05). Compared with the OGD/R group, there was no significant difference in the siRNA-NC group; compared with the siRNA-NC group, the viability of cells was decreased significantly (P<0.01); ROS levels were significantly increased (P<0.01), the expressions of Nrf1 and Bax were increased markedly, and the expressions of bcl-2 was decreased significantly (P<0.05) in Nrf1-siRNA-2 group. CONCLUSION: Nrf1 attenuates neuronal injury caused by oxygen glucose deprivation/reperfusion via inhibiting apoptosis.
    Study on the mechanism of pinoresinol diglucoside on angiogenesis during osteoporotic fracture healing
    WANG Jie, TIAN Shuo, LI Yilin, WEI Jun, MA Yu, LIU Yanqiu
    2025, 30(1):  20-31.  doi:10.12092/j.issn.1009-2501.2025.01.003
    Asbtract ( 29 )   PDF (7285KB) ( 12 )  
    Related Articles | Metrics
    AIM: To explore the regulatory mechanism of pinoresinol diglucoside (PDG) on angiogenesis during osteoporotic fracture healing in vivo and in vitro. METHODS: Fifty male C57BL/6J mice were randomly divided into five groups: normal group, model group, PDG 0.005, 0.015 g/kg groups, and parathyroid hormone 1-34 (PTH1-34) 4×10-5 g/kg group. The osteoporotic fracture model of ovariectomized combined with femoral fracture was established, the PDG group was given intragastric administration every other day and the PTH1-34 group was given subcutaneous injection of PTH1-34 every other day for 8 weeks. Micro-CT scanning, immunofluorescence and immunohistochemical staining were used to detect the related parameters and protein expressions. Human umbilical vein endothelial cells (HUVECs) were cultured, normal group, PDG 1, 10, 100 μmol/L groups and PTH1-34 1 ng/mL group were set up. CCK-8 assay, scratch experiment, tubule formation experiment, immunofluorescence and Western blot were used to detect the related parameters and protein expressions. RESULTS: In vivo experiments found, compared with the normal control group, a small amount of bone callus volume of fracture site were increased in the model control group, while BMD of non-callus site of femur, trabecular bone fraction (BV/TV), trabecular thickness (Tb. Th) and trabecular number (Tb. N) were decreased (P<0.01), and trabecular separation (Tb. Sp) was increased (P<0.01). The positive expression of vascular endothelial marker vascular endothelial markers (CD31) was decreased (P<0.01). Compared with mice in the model control group, bone callus volume, index of BMD and BV/TV were increased in the PDG 0.005 g/kg group (P<0.05), index of BMD, BV/TV, Tb. Th, Tb. N were increased, and index of Tb. Sp was decreased in the PDG 0.015 g/kg group (P<0.05), the positive expression of CD31 was increased in the PDG administration groups (P<0.01), the protein expressions of vascular endothelial growth factor (VEGF-A) (P<0.01), Yes-associated protein 1 (YAP1) (P<0.01), PDZ-binding motif (TAZ) (P<0.05) and TEA domain transcription factor 2 (TEAD2) (P<0.01) were increased in callus in the PDG 0.015 g/kg groups. Cell experiments found, compared with the normal control group, PDG groups promoted the proliferation, migration and tubule formation activity of HUVECs to varying degrees (P<0.05), at the same time, the expression of endothelial cadherin (E-cadherin) was decreased (P<0.01), and VEGF-A, TEAD2, TAZ and YAP1 protein expression were increased (P<0.05). CONCLUSION: PDG may accelerate osteoporotic fracture healing by promoting bone angiogenesis through regulating Hippo signal pathway.
    Exploring the mechanism of Xin Mai Jia in inhibiting hypertensive cardiac hypertrophy based on network pharmacology and animal experiments
    LEI Chengjing, YU Miao, LI Yange, TANG Xiaoguang, ZHAO Fanrong, ZHU Tiantian
    2025, 30(1):  32-41.  doi:10.12092/j.issn.1009-2501.2025.01.004
    Asbtract ( 30 )   PDF (4635KB) ( 16 )  
    Related Articles | Metrics
    AIM: To exploring the mechanism of Xin Mai Jia (XMJ) in inhibiting hypertensive cardiac hypertrophy through network pharmacology and animal experiments. METHODS: Retrieving the active ingredients and target points of XMJ by searching the TCMSP database and related literature reports; using the Gene Cards, OMIM, and Drug Bank databases to screen targets for hypertensive cardiac hypertrophy; constructing a network of traditional Chinese medicine-active ingredients-potential targets and a protein-protein interaction (PPI) network; using DAVID software for target gene ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis; using Auto Dock software for molecular docking. A spontaneously hypertensive rat (SHR) model was established, and hematoxylin-eosin (HE) staining was used to detect the morphology of cardiac tissue and cellular hypertrophy, Masson staining was used to detect collagen deposition in cardiac tissue, and Western blot to detect the expression of heat shock protein (HSP90AA1), mammalian target of rapamycin (mTOR), peroxisome proliferator-activated receptor γ (PPARG), and tumor necrosis factor (TNF-α) in cardiac tissue. RESULTS: A total of 56 potential active ingredients were identified in XMJ, and 5,492 targets related to hypertensive cardiac hypertrophy were obtained. The targets in the core network were ranked according to their Degree values, and four main targets were selected: HSP90AA1, mTOR, PPARG, and TNF-α. The results of HE staining showed that compared with the normal group, the average area of cardiomyocytes in the SHR group increased significantly (P<0.05), while there was no significant change in the XMJ group. The hypertrophy in the SHR+XMJ group was significantly alleviated (P<0.05). The results of Masson staining showed that compared with the normal group, the levels of interstitial fibrosis and perivascular fibrosis in the SHR group rats increased significantly (P<0.01), and XMJ could significantly reduce the fibrosis levels in the SHR group rats (P<0.01). The results of Western blot showed that compared with the normal group rats, the expression of HSP90AA1 and PPARG in the myocardial tissue of SHR group rats was downregulated, mTOR phosphorylation was downregulated, and TNF-α was significantly upregulated (P<0.01). In the SHR+XMJ group, the expression of HSP90AA1, PPARG, and TNF-α in the myocardial tissue of rats returned to normal levels, and mTOR phosphorylation returned to normal levels. In the XMJ group, there were no significant changes in the above indicators compared with the normal group rats. CONCLUSION: The mechanism underlying the inhibitory effect of XMJ on myocardial cell hypertrophy in hypertension involves a comprehensive action through multiple components, multiple targets, and multiple pathways.
    Effects of emodin on autophagy and apoptosis in rats with severe pneumonia caused by Klebsiella pneumoniae by regulating SIRT1/AMPK signaling pathway
    SONG Xiaoping, LIU Pingping, LIU Xiaolin, ZHENG Yan, SUN Bin, DING Jian, ZHU Yuanqi, LI Junfeng
    2025, 30(1):  42-50.  doi:10.12092/j.issn.1009-2501.2025.01.005
    Asbtract ( 39 )   PDF (4094KB) ( 12 )  
    Related Articles | Metrics
    AIM: To investigate the effects of emodin on autophagy and apoptosis in rats with severe pneumonia (KP) caused by K. pneumoniae and its possible mechanism. METHODS: The KP rat model was established by infecting K pneumonia was treated with Emodin. The rats were grouped into Sham surgery group, KP group, low concentration Emodin group, medium concentration Emodin group, high concentration Emodin group, and Emodin+sirtinol (SIRT1 activity inhibitor) group; Arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen (PaO2) and arterial oxygen saturation (SaO2) were measured by blood gas analyzer; the white blood cells and neutrophils in bronchoalveolar lavage fluid (BALF) were measured by Wright-Giemsa staining; HE staining was applied to detect pathological changes in lung tissue in each group; ELISA was applied to detect the expression of IL-6, TNF-α, and IL-1β in lung tissues of each group; electron microscopy scanning was applied to observe the autophagy of cells in lung tissues of each group; the expression of LC3B in lung tissues was observed by immunofluorescence staining; TUNEL method was applied to detect changes in cell apoptosis in lung tissue of rats in each group; Western blot was applied to detect the expression of silent information regulatory factor (SIRT1), adenosine monophosphate activated protein kinase (AMPK), LC3-II, LC3-I, c-caspase-3, and caspase-3 proteins in lung tissue. RESULTS: K. pneumoniae caused severe lung tissue damage in rats with pneumonia, increased inflammatory infiltration and cytokine release in the lungs, arterial blood PaO2 and SaO2 levels decreased, PaCO2 levels increased, white blood cells and neutrophils count increased in BALF, increased cell apoptosis rate and c-caspase-3/caspase-3 level, and the cell autophagy and the levels of autophagy related proteins LC3-II/LC3-I were decreased (all P<0.05), after Emodin treatment, SIRT1/AMPK signaling pathway was activated, PaO2 and SaO2 levels in arterial blood were increased, PaCO2 levels was decreased, inflammatory reaction was inhibited, cell apoptosis in lung tissue was inhibited (all P<0.05), and cell autophagy level was restored, sirtinol, a SIRT1 inhibitor, partially reversed the therapeutic effect of Emodin on KP rats after inhibiting SIRT1/AMPK signaling pathway (P<0.05). CONCLUSION: Emodin may enhance autophagy of lung tissue cells and inhibit apoptosis of rat lung tissue cells by activating SIRT1/AMPK pathway, which may provide potential therapeutic options for KP.
    Effects and mechanism of ethanol extract of Angelica sinensis (Oliv.) Diels on cell proliferation inhibition and apoptosis induction in B16-F10 melanoma cells
    KE Jiajie, SHEN Yuzhou, XU Yaping, CHEN Yupei, CHEN Peiyuan, WU Hongtan
    2025, 30(1):  51-60.  doi:10.12092/j.issn.1009-2501.2025.01.006
    Asbtract ( 29 )   PDF (2211KB) ( 15 )  
    Related Articles | Metrics
    AIM: To explore the effect and mechanism of ethanol extract of Angelica sinensis?(Oliv.) Diels (EEA) on cell proliferation and apoptosis in B16-F10 melanoma cells. METHODS: Cell viability was analyzed by MTT method. Cell proliferation was detected by colony formation assay. The inverted microscope was used to observe the changes of cell growth confluence and morphology. Hoechst 33342 staining was used to detect cell apoptosis. Flow cytometry (FCM) was used to detect cell cycle and apoptosis. Transmission electron microscopy (TEM) was used to observe the changes of cell mitochondrial structure. Western blot was used to detect the expression levels of cell cycle, apoptosis, mitochondrial biogenesis, and mitochondrial dynamics-related proteins. RESULTS: Compared with the blank control group, the cell viability of B16-F10 melanoma cells was reduced after EEA (10-400 μg/mL) treatment for 24 h and 48 h, respectively (P<0.05, P<0.01). The decreased cell growth confluence, morphological changes such as shrinkage, rounding, and reduction in the volume, and apoptotic?morphologic?changes such as chromatin condensation were observed after EEA (100 μg/mL and 200 μg/mL) treatment for 24 h. The number of cell clones was decreased after EEA (10-200 μg/mL) treatment for 14 d (P<0.01). The morphology of mitochondria became more round and shorter, and the inner mitochondrial matrices were either damaged or absent after 200 μg/mL EEA treatment for 24 h. The ratio of cells in G0/G1 phase and the early apoptosis rate of cells were higher than those of the blank control group (P<0.01) after EEA (20-200 μg/mL) treatment for 24 h. Western blot results showed that compared with the blank control group, the protein expression levels of cleaved caspase-9, Bax, DRP1, and FIS1 were up-regulated (P<0.05, P<0.01), and the protein expression levels of cyclin D1, cyclin E, CDK2, CDK4, Bcl-2, Bad, Bcl-XL, SIRT1, PGC-1α, NRF1, TFAM, MFN2, and OPA1 were down-regulated (P<0.05, P<0.01). CONCLUSION: EEA has an inhibitory effect on the proliferation of B16-F10 melanoma cells, which may be related to the induction of G1/S cell cycle arrest and mitochondrial apoptotic pathway, and the disruption of mitochondrial biogenesis and mitochondrial dynamics.
    Plumbagin ameliorates pulmonary fibrosis by modulating TGF-β1/Smad2 and Nrf2/NOX4 pathways
    LI Hui, HU Hengzhao, YU Tingting, HU Huixian, WANG Jiale, WU Jing, HAO Wei
    2025, 30(1):  61-69.  doi:10.12092/j.issn.1009-2501.2025.01.007
    Asbtract ( 30 )   PDF (1839KB) ( 9 )  
    Related Articles | Metrics
    AIM: To investigate the protective effect of plumbagin (PL) against pulmonary fibrosis (PF) and its possible mechanisms. METHODS: Sixty male C57BL/6 mice were randomly divided into control, bleomycin group (BLM), low dose PL group (1 mg/kg) and high dose PL group (2 mg/kg). The mice PF model was replicated using intratracheal injection of BLM (3 mg/kg),  and then PL (1 or 2 mg/kg) was injected intraperitoneally for 3 weeks and the animals were executed. HE and Masson staining were used to observe morphological changes in lung tissue and collagen deposition. The activities or levels of superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA) and hydroxyproline (HYP) were measured in mouse lung tissue; ELISA for interleukin-6 (IL-6) in mouse lung tissue. Immunohistochemical detection of nuclear factor-related factor 2 (Nrf2) and reduced nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4)  positive cell expression in mouse lung tissue. The expression levels of α-smooth muscle actin (α-SMA), collagen I (Col I), collagen III (Col III), IL-6, transforming growth factor-β1 (TGF-β1), p-Smad2, Nrf2 and NOX4 were detected by Western blotting. RESULTS: Compared with the BLM group, PL treatment attenuated lung parenchymal and interstitial injury and extracellular matrix deposition in mice, reduced HYP content (P<0.01, P<0.05), decreased protein expression of α-SMA, collagen I and III (P<0.01, P<0.05), diminished IL-6 secretion (P<0.01); improved the body's antioxidant capacity (increased SOD and GSH activity and decreased MDA content, P<0.01, P<0.05), significantly down-regulated TGF-β1, p-Smad2 and NOX4-positive cells and protein expression (P<0.01, P<0.05) and up-regulated Nrf2-positive cells and protein expression (P<0.01, P<0.05). CONCLUSION: PL may slow down the PF process by modulating the TGF-β1/Smad2 and Nrf2/NOX4 pathways to attenuate inflammatory responses and collagen deposition and improve the body's antioxidant capacity.
    Population pharmacokinetics of high-dose methotrexate in pediatric patients with diverse malignancies
    GONG Yan, GONG Weijing, LI Jiaxin, QIN Yanjie, LUO Li
    2025, 30(1):  70-77.  doi:10.12092/j.issn.1009-2501.2025.01.008
    Asbtract ( 23 )   PDF (1974KB) ( 14 )  
    Related Articles | Metrics
    AIM: To establish a population pharmacokinetic (PPK) model of high-dose methotrexate in pediatric patients with diverse malignancies. METHODS: The PPK model of methotrexate was developed using non-linear mixed-effects model; body surface area (BSA) was incorporated by allometric size modelling. RESULTS: A two-compartment linear model best fitted the concentration data, typical values for clearance (CL) and central compartment distribution volume (Vd) were revealed to be 4.51 L/(h·1.73 m2) and 15.47 L/1.73 m2, respectively. Age, BSA, serum creatinine (SCr) and genotypes of ABCC2 rs717620 and ABCC4 rs2274407 were retained in the final model. CONCLUSION: Age, BSA, SCr and genotypes of ABCC2 rs717620 and ABCC4 rs2274407 were identified to be significantly affecting the clearance. 
    Effects of esketamine-mediated opioid-free anesthesia on delirium in elderly patients after hip replacement
    HUA Hao, HE Teng, LI Xin, CHEN Xiaodong, LIU Zhenqing, LIU Kun, ZHANG Qi, JIANG Lin, LIU Cunming, WANG Meng, YANG Chun
    2025, 30(1):  78-84.  doi:10.12092/j.issn.1009-2501.2025.01.009
    Asbtract ( 35 )   PDF (790KB) ( 10 )  
    Related Articles | Metrics
    AIM: To observe the effect of opioid-free anesthesia with esketamine on delirium after hip replacement surgery in elderly patients. METHODS: One hundred and fourteen elderly patients who underwent hip replacement were randomly divided into two groups: opioid-free anesthesia (OFA) group and opioid anesthesia (OA) group (n=57). During anesthesia induction and maintenance, esketamine was administered in OFA group, and that fentanyl and remifentanil were administered in OA group. Delirium was mainly recorded within 3 days after the surgeries, and the patients' delirium status was evaluated using the Chinese Revised Delirium Diagnostic Scale (CAM-CR). RESULTS:The patients in OFA group had lower CAM-CR scores and delirium incidence compared to those in the OA group at 2 days after surgery. CONCLUSION: Opioid-free anesthesia based on esketamine can effectively reduce delirium after hip replacement in elderly patients.
    Application of ultrasound-guided erector spinae plane block in extracorporeal shock wave lithotripsy for pancreatic duct stones
    WANG Yue, CHENG Yong, TAO Haiyong, HE Xiaoye, HU Liuxin, XIE Xiaoyi, GUO Jianrong
    2025, 30(1):  85-90.  doi:10.12092/j.issn.1009-2501.2025.01.010
    Asbtract ( 25 )   PDF (765KB) ( 10 )  
    Related Articles | Metrics
    AIM: To evaluate the value of ultrasound-guided erector spinae plane block (ESPB) combined with opioid-sparing anaesthesia in extracorporeal shock wave lithotripsy (ESWL) for pancreatic stones. METHODS: A total of 96 patients (60 males and 36 females, aged 20-65 years, ASA I-II, BMI 16-30 kg/m2) undergoing elective extracorporeal shock wave lithotripsy for pancreatic duct stones were selected in our hospital from March 2022 to April 2023. The patients were randomly divided into conventional intravenous anesthesia group (group C, 48 cases) and ESPB+ opioid-sparing group (group E, 48 cases). Patients in group C underwent general anesthesia with target-controlled infusion of propofol and remifentanil with spontaneous breathing. Patients in group E underwent ultrasound-guided bilateral ESPB before intravenous general anesthesia. The changes of hemodynamic indexes (HR, MAP) in the two groups were observed and recorded. The anesthetic effect, dosage of remifentanil, quality of anesthesia recovery, postoperative analgesic effect and incidence of perioperative adverse reactions (respiratory depression, nausea and vomiting, pruritus, etc.) were observed in the two groups. RESULTS: Compared with group C, the incidence of intraoperative respiratory depression was significantly decreased, the intraoperative consumption of remifentanil was decreased, and the postoperative recovery time was shortened in group E (P<0.05). The VAS scores of rest and cough pain and the incidence of postoperative nausea and vomiting were significantly decreased in group E (P<0.05). There was no significant difference in HR and MAP between the two groups (P>0.05). CONCLUSION: Ultrasound-guided ESPB in ESWL for pancreatic duct stones is satisfactory and can save opioids with few complications.
    Current clinical application and research progress of antiplatelet drugs
    PAN Guanxing, HUANG Pinfang, CHAI Dajun, ZHANG Jing
    2025, 30(1):  91-99.  doi:10.12092/j.issn.1009-2501.2025.01.011
    Asbtract ( 33 )   PDF (934KB) ( 19 )  
    Related Articles | Metrics
    Arterial thrombosis is a major cause of death in several cardiovascular diseases (CVDs), including coronary heart disease and stroke. Since platelets play a pivotal role in arterial thrombosis, antiplatelet drug is an important part of the clinical therapy of CVD patients. Currently, the long-term antithrombotic effect of the dual antiplatelet therapy of P2Y12 antagonists combined with aspirin are showed to be effective. And αΙIbβ3 antagonists represented by tirofiban are widely used for antiplatelet therapy in emergency surgery. However, the bleeding risk caused by antiplatelet therapy is a clinical issue that cannot be ignored. In order to provide a reference for further research on antiplatelet drugs, this article reviews the major targets of antiplatelet drugs and the drugs that have been under clinical research in recent years.
    Drug resistance of tyrosine kinase inhibitors in renal cell carcinoma
    QIAN Hanxu, ZHAO Yaxuan, YANG Yang, ZHANG Yin
    2025, 30(1):  100-109.  doi:10.12092/j.issn.1009-2501.2025.01.012
    Asbtract ( 36 )   PDF (1823KB) ( 15 )  
    Related Articles | Metrics
    Tyrosine kinase inhibitors (TKIs) are the key agent in the treatment of renal cell carcinoma (RCC) so far. Drugs such as sunitinib and sorafenib showed significant benefits RCC patients, however, the adverse effect, drug efficacy and drug resistance limited the use of these therapy. Especially the drug resistant issue brings up a big challenge for clinical practice, and the mechanisms underlying are still poorly understood. In recent years, new therapies have been combined with TKIs to improve the treatment outcome. Immunotherapy, combination therapy with other TKIs, targeted nanoparticle delivery, and drug modification are widely studied to improve the efficacies of TKIs and regain the sensitivity. In this review, we summarizes the current understanding of TKI drug resistance and the approaches to regaining drug sensitivity.
    Progress of macrophage regulation mechanism in acute renal injury
    DUAN Yuxin, ZHANG Yanni, BAI Yi, YU Jinyao, SUN Jiayi, WANG Zejie, LI Ling, YE Qifa
    2025, 30(1):  110-117.  doi:10.12092/j.issn.1009-2501.2025.01.013
    Asbtract ( 32 )   PDF (1264KB) ( 12 )  
    Related Articles | Metrics
    Acute kidney injury (AKI) is a syndrome characterized by rapid decline in renal excretory function. Its pathogenesis is still unclear. Studies have shown that macrophages are major players in AKI inflammation, regulating tissue damage and regeneration repair. During AKI inflammation, macrophages can be activated into different functional phenotypes through molecular and signaling pathways, regulate different molecules and signaling pathways, and determine the progression of AKI. In this paper, the activation of macrophages and the molecular signaling pathways involved in the regulation of AKI in the past five years are reviewed, and the mechanism of action of macrophages in AKI is determined, which provides ideas for the study of macrophages as therapeutic targets.
    Research progress in the study of melatonin in the treatment of sepsis
    LI Nan, TANG Wanchun, ZHANG Zhongqi, ZUO Xiangrong
    2025, 30(1):  118-124.  doi:10.12092/j.issn.1009-2501.2025.01.014
    Asbtract ( 29 )   PDF (636KB) ( 13 )  
    Related Articles | Metrics
    Sepsis poses a significant threat to human health due to its widespread prevalence, high mortality rate, substantial treatment costs, and the absence of effective life-saving therapies. Melatonin, a primary hormone regulating the circadian rhythm, has demonstrated potential as a promising therapeutic agent against sepsis. Its anti-inflammatory, antioxidant, immunomodulatory, mitochondrial protective, and multi-organ protective effects are noteworthy. In this review, we summarize current research on the mechanisms of action and clinical efficacy of melatonin in sepsis treatment and multi-organ function preservation, aiming to offer new perspectives and support for sepsis research and therapy.
    Research progress on the effect of opioids on obstructive sleep apnea
    SUN Jingzi, LIU Weiying, HU Aoyan, BAO Bahu, YE Yucai, CHEN Guorong
    2025, 30(1):  125-130.  doi:10.12092/j.issn.1009-2501.2025.01.015
    Asbtract ( 43 )   PDF (574KB) ( 12 )  
    Related Articles | Metrics
    Obstructive sleep apnea (OSA) is a disorder characterized by chronic intermittent hypoxia and sleep fragmentation, usually manifested by obstruction of the upper respiratory tract, resulting in sleep fragmentation, intermittent hypoxia, and hypercapnia.OSA and significant comorbidities are associated with perioperative complications. Opioids, as the most commonly used pain relievers, may further affect perioperative pain management in OSA and comorbidities. Studies have shown that OSA patients are more susceptible to the respiratory depressant effects of opioids.OSA also increases the risk of opioid-induced respiratory depression.Therefore, understanding the effects and mechanisms of opioids on OSA has important clinical significance for optimizing drug use, improving prognosis, and reducing respiratory adverse events.This article aims to review the effects of opioids on OSA and their relationship.
    Analysis and discussion of the common problems found in medical device clinical trials inspection results from 2016 to 2023
    LIANG Yuyan, JI Fang, PAN Ying, XU Shiyao, YANG Shu, XU Liang
    2025, 30(1):  131-137.  doi:10.12092/j.issn.1009-2501.2025.01.016
    Asbtract ( 28 )   PDF (869KB) ( 16 )  
    Related Articles | Metrics
    By collecting inspection results from medical device clinical trials from 2016 to 2023, to analyze and discuss?common problems of clinical trials?from both?in vitro diagnostic reagents and medical devices, and propose the suggested measures taken by participants in the clinical trial, so as to avoid similar problems?occur?and ensure the quality of clinical trials.
    Analysis and reflections on the characteristics of highly cited papers in Chinese Journal of Clinical Pharmacology and Therapeutics from 2014 to 2023
    LI Juan, ZHONG Zhengling, CHU Jiru, PENG Jingya, YU Wentao
    2025, 30(1):  138-144.  doi:10.12092/j.issn.1009-2501.2025.01.017
    Asbtract ( 30 )   PDF (926KB) ( 11 )  
    Related Articles | Metrics
    This paper analyzes the characteristics of highly cited papers published in Chinese Clinical Pharmacology and Therapeutics in the past ten years, in order to explore the influence and research value of these papers. Highly cited papers are an important index to evaluate the scientific research level of scholars and research institutions, so this study focuses on the characteristics of their number, citation frequency, number of co-authors and regional distribution. The paper uses bibliometrics to analyze the publication trend and citations of highly cited papers. The results show that during the observation period, the number of highly cited papers decreases year by year, and there is a significant correlation between cited frequency and publication time. In addition, the number of co-authors presents a normal distribution, among which the number of co-authors is the largest, indicating that moderate cooperation has a positive effect on the influence of papers. From the perspective of geographical distribution, the author group of the magazine is relatively dispersed, covering many regions of the country, among which Anhui, Hunan and Zhejiang have become the main sources of high-quality manuscripts. The finding reflects the magazine's wide reach across the country. The results of this study provide empirical support for understanding the characteristics of highly cited papers and emphasize the importance of research collaboration and geographical factors in research publication. Through the analysis of highly cited papers, this paper provides references for subsequent researchers in selecting research topics and cooperation methods, and also provides beneficial suggestions for improving the research level and influence of clinical pharmacology in China.